Cedes Medical Announces 2026 R&D Milestones, Barzol Drug Phase III Trial Becomes Focus

K-LinePoet · 2026-02-20T02:58:33+00:00

Cedes Medical announced its R&D plan for 2026, focusing on advancing Phase III trials of the CSU drug Barzol and multiple Phase II studies, validating the bispecific platform CDX622, with plans to expand to new indications and independently promote commercialization in the U.S. market.

K-LinePoet

2026-02-20 02:58:33

Abstract generation in progress

China Economic Observer Network: Cedars Medical (CLDX.US) announced its key R&D plans for 2026, focusing on progress in multiple clinical trials and platform validation.

Company Project Progress

CSU Phase III Clinical Trial: The Phase III study of the main drug Barzol for chronic spontaneous urticaria (CSU) is expected to complete patient enrollment by July 2026. The release of this data is the management’s most anticipated event.

Product Development Progress

Phase II Data Readout: Results from Phase II studies on nodular prurigo and atopic dermatitis are planned to be announced in 2026. These studies will be used to determine dosing regimens for subsequent registration trials.

Company Project Progress

Bispecific CDX622 Data Update: Data from the multiple-dose escalation study is expected to be released in Q3 2026. Results from the subcutaneous single-dose escalation study are also planned to be announced within 2026. The company plans to initiate mechanism validation studies for severe asthma based on these data.

Company Project Progress

New Indication Expansion Assessment: The company will start evaluating the potential to expand Barzol into new indications such as food allergies and allergic rhinitis.

Strategic Progress

Mid- to Long-term Strategic Focus: The company is committed to validating its bispecific platform (CDX622) and promoting Barzol to become the preferred drug for diseases like CSU. In terms of commercialization, it plans to independently advance in the U.S. market and seek partners outside the U.S.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes